Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01031628 · ClinicalTrials.gov registry record · Phase 3
Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients
A Phase 3 study, sponsored by Sarcoma Alliance for Research through Collaboration.
- Terminated
- Registry status
- Phase 3
- Development phase
- 5
- Enrollment target
NCT01031628: Clinical Trial Phase 3 study, sponsored by Sarcoma Alliance for Research through Collaboration.
NCT01031628 is a Phase 3 study that was terminated before completion, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 5 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01031628, a Phase 3 study, was terminated before completion, sponsored by Sarcoma Alliance for Research through Collaboration.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if escalating the dose of imatinib to keep the drug blood level at ≥ 1100 ng/ml leads to better outcomes for patients.
Interventions
- DRUG Imatinib mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-06 |
| Phase | Phase 3 |
Why NCT01031628 stopped before completion
NCT01031628 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Imatinib mesylate is the first listed.
NCT01031628 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01031628 about?
NCT01031628 is a clinical study titled "Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients". The purpose of this study is to determine if escalating the dose of imatinib to keep the drug blood level at ≥ 1100 ng/ml leads to better outcomes for patients.
What is the current status of trial NCT01031628?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 5 participants. The study started on 2010-01. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01031628?
The interventions under investigation include: Imatinib mesylate (DRUG).
Who is sponsoring clinical trial NCT01031628?
This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01031628's enrollment target sits among peer trials
5 1997th of 2000 higher than 3 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia